Like_老虎社区_美港股上老虎

BubTigger
2021-11-09

BioNTech’s Success Offers Antidote to EU Biopharma Skittishness

(Bloomberg) -- Covid-19 vaccine maker BioNTech SE’s success is having a ripple effect for younger co

BioNTech’s Success Offers Antidote to EU Biopharma Skittishness

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":844569857,"tweetId":"844569857","gmtCreate":1636442020605,"gmtModify":1636442021091,"author":{"id":3583137386609574,"idStr":"3583137386609574","authorId":3583137386609574,"authorIdStr":"3583137386609574","name":"BubTigger","avatar":"https://static.tigerbbs.com/80f5d5f05e07b454afdd935e835160d7","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":28,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Like</p></body></html>","htmlText":"<html><head></head><body><p>Like</p></body></html>","text":"Like","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/844569857","repostId":2182037377,"repostType":4,"repost":{"id":"2182037377","kind":"news","pubTimestamp":1636441440,"share":"https://www.laohu8.com/m/news/2182037377?lang=&edition=full","pubTime":"2021-11-09 15:04","market":"us","language":"en","title":"BioNTech’s Success Offers Antidote to EU Biopharma Skittishness","url":"https://stock-news.laohu8.com/highlight/detail?id=2182037377","media":"Bloomberg","summary":"(Bloomberg) -- Covid-19 vaccine maker BioNTech SE’s success is having a ripple effect for younger co","content":"<p>(Bloomberg) -- Covid-19 vaccine maker <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>’s success is having a ripple effect for younger companies, drawing interest from investors who might previously have been skeptical about the biotechnology sector in Europe, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the German company’s early backers said.</p>\n<p>“I expect more money flowing into the European, particularly German, biotechnology industry through this new excitement,” said Matthias Kromayer, a partner at Munich-based MIG Verwaltungs AG. MIG, a venture capital investor, was among the founding backers of BioNTech, providing 13.1 million euros ($15.2 million). It has returned 600 million euros on that investment in the biggest payout to investors in the firm’s history.</p>\n<p>BioNTech and partner Pfizer Inc. may reap $29 billion in sales next year for their Covid shot, the U.S. company said last week. The vaccine will most likely be this year’s best-selling drug. The race to bring it to the market has helped companies understand ways to speed up drug development, Kromayer said.</p>\n<p>Still, it may take at least a decade for enough critical mass to build for European biotechs to choose their home turf for public offerings instead of the U.S. market, Kromayer said. One factor that could speed up the process would be if the German government were to switch to a capital-based pension system, he said, which could create professional pension funds with more money available for IPO and follow-on offerings.</p>\n<p>Negotiators seeking to hammer out a plan for Germany’s next government are working on details for a first step in that direction. The potential ruling coalition of Social Democrats, Greens and market-oriented Free Democrats is working on a plan for the $400 billion pension system to start investing some of its reserves in stocks and bonds, according to the political roadmap agreed last month by the three parties.</p>\n<p>MIG sold its remaining stake in BioNTech in April. BioNTech’s shares have nearly tripled this year, despite a drop from their August peak as potential Covid antiviral pills delivered positive results in patient trials.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech’s Success Offers Antidote to EU Biopharma Skittishness</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech’s Success Offers Antidote to EU Biopharma Skittishness\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-09 15:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/biontech-success-offers-antidote-eu-050000732.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Covid-19 vaccine maker BioNTech SE’s success is having a ripple effect for younger companies, drawing interest from investors who might previously have been skeptical about the ...</p>\n\n<a href=\"https://finance.yahoo.com/news/biontech-success-offers-antidote-eu-050000732.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://finance.yahoo.com/news/biontech-success-offers-antidote-eu-050000732.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2182037377","content_text":"(Bloomberg) -- Covid-19 vaccine maker BioNTech SE’s success is having a ripple effect for younger companies, drawing interest from investors who might previously have been skeptical about the biotechnology sector in Europe, one of the German company’s early backers said.\n“I expect more money flowing into the European, particularly German, biotechnology industry through this new excitement,” said Matthias Kromayer, a partner at Munich-based MIG Verwaltungs AG. MIG, a venture capital investor, was among the founding backers of BioNTech, providing 13.1 million euros ($15.2 million). It has returned 600 million euros on that investment in the biggest payout to investors in the firm’s history.\nBioNTech and partner Pfizer Inc. may reap $29 billion in sales next year for their Covid shot, the U.S. company said last week. The vaccine will most likely be this year’s best-selling drug. The race to bring it to the market has helped companies understand ways to speed up drug development, Kromayer said.\nStill, it may take at least a decade for enough critical mass to build for European biotechs to choose their home turf for public offerings instead of the U.S. market, Kromayer said. One factor that could speed up the process would be if the German government were to switch to a capital-based pension system, he said, which could create professional pension funds with more money available for IPO and follow-on offerings.\nNegotiators seeking to hammer out a plan for Germany’s next government are working on details for a first step in that direction. The potential ruling coalition of Social Democrats, Greens and market-oriented Free Democrats is working on a plan for the $400 billion pension system to start investing some of its reserves in stocks and bonds, according to the political roadmap agreed last month by the three parties.\nMIG sold its remaining stake in BioNTech in April. BioNTech’s shares have nearly tripled this year, despite a drop from their August peak as potential Covid antiviral pills delivered positive results in patient trials.","news_type":1},"isVote":1,"tweetType":1,"viewCount":841,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}

BioNTech’s Success Offers Antidote to EU Biopharma Skittishness

评论（1）

热议股票